Recent Investment Analysts’ Ratings Changes for Nurix Therapeutics (NRIX)

A number of research firms have changed their ratings and price targets for Nurix Therapeutics (NASDAQ: NRIX):

• 7/13/2026 – Nurix Therapeutics had its price target raised by Mizuho from $30.00 to $34.00. They now have an “outperform” rating on the stock.
• 7/12/2026 – Nurix Therapeutics was upgraded by Wall Street Zen from “strong sell” to “sell”.
• 7/10/2026 – Nurix Therapeutics had its price target raised by Truist Financial Corporation from $32.00 to $34.00. They now have a “buy” rating on the stock.
• 7/10/2026 – Nurix Therapeutics had its price target raised by HC Wainwright from $32.00 to $34.00. They now have a “buy” rating on the stock.
• 7/10/2026 – Nurix Therapeutics had its price target raised by Stifel Nicolaus from $34.00 to $40.00. They now have a “buy” rating on the stock.
• 7/10/2026 – Nurix Therapeutics had its price target raised by Royal Bank Of Canada from $30.00 to $33.00. They now have an “outperform” rating on the stock.
• 7/10/2026 – Nurix Therapeutics had its “buy” rating reaffirmed by Needham & Company LLC. They now have a $34.00 price target on the stock.
• 7/10/2026 – Nurix Therapeutics had its “buy” rating reaffirmed by BTIG Research. They now have a $32.00 price target on the stock.
• 6/29/2026 – Nurix Therapeutics is now covered by Oppenheimer Holdings, Inc.. They set an “outperform” rating and a $28.00 price target on the stock.
• 6/18/2026 – Nurix Therapeutics had its price target raised by Robert W. Baird from $26.00 to $33.00. They now have an “outperform” rating on the stock.
• 6/15/2026 – Nurix Therapeutics had its “buy” rating reaffirmed by Needham & Company LLC. They now have a $34.00 price target on the stock.
• 6/10/2026 – Nurix Therapeutics had its “buy” rating reaffirmed by HC Wainwright. They now have a $32.00 price target on the stock.
• 6/9/2026 – Nurix Therapeutics had its price target raised by BTIG Research from $30.00 to $32.00. They now have a “buy” rating on the stock.
• 6/8/2026 – Nurix Therapeutics had its price target raised by Truist Financial Corporation from $30.00 to $32.00. They now have a “buy” rating on the stock.
• 6/8/2026 – Nurix Therapeutics was downgraded by Wells Fargo & Company from “overweight” to “hold”. They now have a $25.00 price target on the stock, down from $28.00.
• 6/8/2026 – Nurix Therapeutics had its price target raised by Jefferies Financial Group Inc. from $41.00 to $45.00. They now have a “buy” rating on the stock.
• 6/8/2026 – Nurix Therapeutics had its price target raised by Needham & Company LLC from $26.00 to $34.00. They now have a “buy” rating on the stock.
• 5/18/2026 – Nurix Therapeutics had its “buy” rating reaffirmed by BTIG Research. They now have a $30.00 price target on the stock.

Insider Transactions at Nurix Therapeutics

In other news, CFO Houte Hans Van sold 14,055 shares of Nurix Therapeutics stock in a transaction dated Tuesday, May 5th. The shares were sold at an average price of $16.60, for a total value of $233,313.00. Following the completion of the transaction, the chief financial officer owned 37,592 shares of the company’s stock, valued at $624,027.20. This trade represents a 27.21% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Gwenn Hansen sold 5,394 shares of the business’s stock in a transaction dated Thursday, June 25th. The stock was sold at an average price of $20.00, for a total transaction of $107,880.00. Following the transaction, the insider owned 115,005 shares in the company, valued at $2,300,100. This represents a 4.48% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last three months, insiders sold 25,051 shares of company stock valued at $434,466. Insiders own 6.70% of the company’s stock.

Nurix Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of small-molecule therapies that harness the ubiquitin-proteasome system to selectively degrade disease-causing proteins. By modulating E3 ubiquitin ligases and related molecular machinery, Nurix aims to expand treatment options for patient populations with unmet medical needs in oncology and immunology.

The company’s pipeline includes multiple programs in various stages of development.